- Home
- PBFS vs ALDX Comparison
PBFS vs ALDX Comparison
Compare PBFS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- ALDX
- Stock Information
- Founded
- PBFS 1889
- ALDX 2004
- Country
- PBFS United States
- ALDX United States
- Employees
- PBFS N/A
- ALDX N/A
- Industry
- PBFS Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- ALDX Health Care
- Exchange
- PBFS Nasdaq
- ALDX Nasdaq
- Market Cap
- PBFS 309.6M
- ALDX 398.3M
- IPO Year
- PBFS N/A
- ALDX 2014
- Fundamental
- Price
- PBFS $11.56
- ALDX $5.48
- Analyst Decision
- PBFS
- ALDX Strong Buy
- Analyst Count
- PBFS 0
- ALDX 2
- Target Price
- PBFS N/A
- ALDX $10.00
- AVG Volume (30 Days)
- PBFS 18.9K
- ALDX 901.3K
- Earning Date
- PBFS 05-12-2025
- ALDX 05-01-2025
- Dividend Yield
- PBFS N/A
- ALDX N/A
- EPS Growth
- PBFS 11.77
- ALDX N/A
- EPS
- PBFS 0.76
- ALDX N/A
- Revenue
- PBFS $88,118,000.00
- ALDX N/A
- Revenue This Year
- PBFS N/A
- ALDX N/A
- Revenue Next Year
- PBFS N/A
- ALDX N/A
- P/E Ratio
- PBFS $15.41
- ALDX N/A
- Revenue Growth
- PBFS 21.67
- ALDX N/A
- 52 Week Low
- PBFS $8.76
- ALDX $3.10
- 52 Week High
- PBFS $12.20
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PBFS 42.83
- ALDX 37.89
- Support Level
- PBFS $11.49
- ALDX $6.30
- Resistance Level
- PBFS $11.78
- ALDX $6.73
- Average True Range (ATR)
- PBFS 0.20
- ALDX 0.52
- MACD
- PBFS -0.05
- ALDX -0.14
- Stochastic Oscillator
- PBFS 12.50
- ALDX 20.71
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.